Evripidis Lanitis - ARCHIVE

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


21 publications

2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2008 |
2023
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
Corria-Osorio J., Carmona S.J., Stefanidis E., Andreatta M., Ortiz-Miranda Y., Muller T., Rota I.A., Crespo I., Seijo B., Castro W. et al., 2023/05. Nature immunology, 24 (5) pp. 869-883. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B6529135A8DD]
2021
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
Irving M., Lanitis E., Migliorini D., Ivics Z., Guedan S., 2021/10. Human gene therapy, 32 (19-20) pp. 1044-1058. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_24515EABFB7F]
 
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.
Lanitis E., Kosti P., Ronet C., Cribioli E., Rota G., Spill A., Reichenbach P., Zoete V., Dangaj Laniti D., Coukos G. et al., 2021/08. Journal for immunotherapy of cancer, 9 (8) pp. e002151. Peer-reviewed.
[DOI][Pmid][serval:BIB_3B098C62EF15]
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_745449157CA6]
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Lanitis E., Rota G., Kosti P., Ronet C., Spill A., Seijo B., Romero P., Dangaj D., Coukos G., Irving M., 2021/02/01. The Journal of experimental medicine, 218 (2) pp. e20192203. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_75DE24FE756B]
2020
 
All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy.
Lanitis E., Coukos G., Irving M., 2020/10. Current opinion in biotechnology, 65 pp. 75-87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97CF39EFF89C]
miR-155 Overexpression in OT-1 CD8<sup>+</sup> T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.
Monnot G.C., Martinez-Usatorre A., Lanitis E., Lopes S.F., Cheng W.C., Ho P.C., Irving M., Coukos G., Donda A., Romero P., 2020/03/27. Molecular therapy oncolytics, 16 pp. 111-123. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_39DC24C5C585]
2019
 
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95C8776874F3]
2018
Correction to: CART cells are prone to Fas- and DR5-mediated cell death.
Tschumi B.O., Dumauthioz N., Marti B., Zhang L., Lanitis E., Irving M., Schneider P., Mach J.P., Coukos G., Romero P. et al., 2018. Journal for Immunotherapy of Cancer, 6 (1) p. 92. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE20F9B96389]
2017
 
Mechanisms regulating T-cell infiltration and activity in solid tumors.
Lanitis E., Dangaj D., Irving M., Coukos G., 2017/12/01. Annals of oncology, 28 (suppl_12) pp. xii18-xii32. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE2398AAD635]
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.
Facciabene A., De Sanctis F., Pierini S., Reis E.S., Balint K., Facciponte J., Rueter J., Kagabu M., Magotti P., Lanitis E. et al., 2017. Oncoimmunology, 6 (9) pp. e1326442. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_69B217E99597]
2016
 
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith J.B., Lanitis E., Dangaj D., Buza E., Poussin M., Stashwick C., Scholler N., Powell D.J., 2016/11. Molecular therapy : the journal of the American Society of Gene Therapy, 24 (11) pp. 1987-1999. Peer-reviewed.
[DOI][Pmid][serval:BIB_EC7C7B783578]
Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.
Roberti A., Dobay M.P., Bisig B., Vallois D., Boéchat C., Lanitis E., Bouchindhomme B., Parrens M.C., Bossard C., Quintanilla-Martinez L. et al., 2016. Nature Communications, 7 p. 12602. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C7743642D37E]
2015
Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.
Karapetsas A., Giannakakis A., Dangaj D., Lanitis E., Kynigopoulos S., Lambropoulou M., Tanyi J.L., Galanis A., Kakolyris S., Trypsianis G. et al., 2015. Biomed Research International, 2015 p. 712438. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_082FCA6C4652]
Targeting the tumor vasculature to enhance T cell activity.
Lanitis E., Irving M., Coukos G., 2015. Current Opinion in Immunology, 33 pp. 55-63. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_266C11B75B8F]
2014
 
Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.
Giannakakis A., Karapetsas A., Dangaj D., Lanitis E., Tanyi J., Coukos G., Sandaltzopoulos R., 2014. International Journal of Biochemistry and Cell Biology, 53 pp. 389-398.
[DOI][WoS][Pmid][serval:BIB_3EE5F8B4AE65]
2013
 
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D., Lanitis E., Zhao A., Joshi S., Cheng Y., Sandaltzopoulos R., Ra H.J., Danet-Desnoyers G., Powell D.J., Scholler N., 2013/08/01. Cancer research, 73 (15) pp. 4820-4829. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_74E16544B1E9]
2012
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.
Lanitis E., Dangaj D., Hagemann I.S., Song D.G., Best A., Sandaltzopoulos R., Coukos G., Powell D.J., 2012. Plos One, 7 (11) pp. e49829.
[DOI][WoS][Pmid][serval:BIB_8DF38EB47D0C]
Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Lanitis E., Poussin M., Hagemann I.S., Coukos G., Sandaltzopoulos R., Scholler N., Powell D.J., 2012. Molecular Therapy, 20 (3) pp. 633-643.
[DOI][WoS][Pmid][serval:BIB_9D72B6BBBB7A]
2011
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.
Chiang C.L., Maier D.A., Kandalaft L.E., Brennan A.L., Lanitis E., Ye Q., Levine B.L., Czerniecki B.J., Powell D.J., Coukos G., 2011. Journal of Translational Medicine, 9 p. 198.
[DOI][WoS][Pmid][serval:BIB_D6501BDAE8F7]
2008
Reactive oxygen species and HIF-1 signalling in cancer.
Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R., 2008/07/18. Cancer letters, 266 (1) pp. 12-20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A1D91B548B6]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University